

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



IMPACT Therapeutics, Inc
南京英派藥業股份有限公司

(A joint stock company established in the People's Republic of China with limited liability)

(Stock Code: 7630)

VOLUNTARY ANNOUNCEMENT

**POSTER PRESENTATION OF LATEST CLINICAL DATA FOR
SENAPARIB AND PARP1-SELECTIVE INHIBITORS IMP1734
AND IMP1707 AT 2026 ESMO CONGRESS**

This announcement is made by IMPACT Therapeutics, Inc (the “**Company**”, together with its subsidiaries, the “**Group**” or “**IMPACT**”) on a voluntary basis to inform the Company’s shareholders and potential investors about the latest business update of the Group.

The Company is pleased to announce that the latest clinical data for its pipeline drugs, senaparib (IMP4297), IMP1734 (also known as EIK1003) and IMP1707 (also known as EIK1004), have been presented as posters at the 2026 European Society for Medical Oncology (ESMO) Congress, being held from October 23 to 27, 2026 in Madrid, Spain.

THE DATA PRESENTED INCLUDE:

Senaparib (FLAMES Study): Updated Phase 3 PFS data demonstrating first-line maintenance benefit in advanced ovarian cancer **regardless of BRCA mutation status**

IMP1734 (EIK1003): Updated Phase 1/2 results across monotherapy and combination cohorts (with paclitaxel in advanced solid tumors; with abiraterone in metastatic prostate cancer)

IMP1707 (EIK1004): Initial Phase 1/2 results for this **CNS-penetrant, selective PARP1 inhibitor** in patients with HRR-mutated advanced solid tumors

THE KEY HIGHLIGHTS OF THE STUDY PRESENTED AT THE ESMO 2026 MEETING ARE AS FOLLOWS:

Senaparib (IMP4297)

Title: Updated Progression-Free Survival (PFS) Results from the FLAMES Study: First-Line Maintenance Senaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer (aOC)

Abstract #: 1260P

Senaparib Clinical Update:

At a median follow-up of 48.5 months, senaparib continued to demonstrate a consistent and statistically significant PFS benefit over placebo in the overall patient population, with a median PFS of 38.7 months versus 13.6 months as assessed by BICR (HR=0.47; 95% CI: 0.36, 0.62; $p<0.0001$). Importantly, the PFS benefit was consistent across both BRCAm and BRCAwt patient subgroups, with a median PFS of 49.8 months versus 15.6 months (HR=0.41; 95% CI: 0.25, 0.70) in BRCAm patients and 33.3 months versus 12.9 months (HR=0.49; 95% CI: 0.36, 0.68) in BRCAwt patients, reinforcing the clinical benefit of senaparib regardless of BRCA mutation status.

IMP1734 (EIK1003)

Title: Phase 1/2 study of a PARP1-selective inhibitor, EIK1003, in combination with abiraterone in patients with metastatic prostate cancer (mPC)

Abstract #: 1049P

IMP1734 Cohort 1B (combination with abiraterone) clinical update:

IMP1734 with abiraterone demonstrated a tolerable safety profile and encouraging antitumor activity across all DLs in a heavily pre-treated Metastatic Prostate Cancer (mPC) population. Anemia (15%) was the sole Grade ≥ 3 hematologic TEAE observed at an incidence of $\geq 10\%$, suggesting a favorable hematologic safety profile consistent with its high selectivity for PARP1. Responses were observed in participants with both BRCA- and non-BRCA HRR alterations, including ATM, suggesting potential activity across a broader HRR-altered population. Among 24 efficacy-evaluable participants, ORR was 19.0% (4/21) in mCRPC, and 33.3% (1/3) in mCSPC, respectively. Among 39 PSA-evaluable participants, PSA response (PSA50) was 26.5% (9/34) in mCRPC, and 60.0% (3/5) in mCSPC. These data support the combinability of a PARP1-selective inhibitor with androgen receptor pathway inhibitor.

Title: Phase 1/2 study of a PARP1-selective inhibitor, EIK1003, as monotherapy and in combination with paclitaxel (PTX) in advanced solid tumors

Abstract #: 1048P

IMP1734 cohort 1A and 1C (monotherapy and combination with paclitaxel) clinical update:

Extended follow-up of IMP1734 monotherapy (Cohort 1A) confirmed a favorable safety profile and durable responses in a heavily pre-treated HRR-mutated population. The incidences of Grade ≥ 3 anemia and neutropenia were low, at 9.2% and 7.7%, respectively. In this heavily pre-treated population, the ORR was 14.3%, with 1 responder remaining on treatment for over 21 months.

In Cohort 1C, IMP1734 plus weekly paclitaxel exhibited a manageable safety profile in biomarker-unselected participants with advanced ovarian and breast cancer. The hematologic toxicity profile was comparable to that historically observed with weekly paclitaxel monotherapy, with Grade ≥ 3 neutropenia and anemia reported in 49.2% and 18.0% of participants, respectively, suggesting no substantial additive hematologic toxicity from the combination. Encouraging antitumor activity was observed despite extensive prior exposure to both taxanes and PARP inhibitors (PARPi). ORR was 29.6% (8/27) in ovarian cancer, and 23.1% (6/26) in breast cancer, respectively. Among the 14 responders, 12 had received prior taxane therapy, and 9 had been previously treated with a PARPi. Notably, in PARPi-pre-treated participants, the ORR was 38.1% (8/21) in ovarian cancer, indicating clinical benefit even after prior PARPi failure. These findings provide the first clinical evidence that a PARP1-selective inhibitor can be safely combined with cytotoxic chemotherapy, with antitumor activity retained despite prior taxane and PARPi exposure, thereby addressing a population with high unmet medical need.

IMP1707 (EIK1004)

Title: A first-in-human Phase 1/2 study of EIK1004, a PARP1-selective CNS-penetrant inhibitor, in patients with advanced solid tumors with HRR mutations

Abstract #: 1060P

IMP1707 Clinical Update:

IMP1707 demonstrated a favorable safety profile consistent with its selective PARP1 mechanism of action. Hematologic toxicity was minimal, with Grade ≥ 3 anemia and neutropenia each occurring in only 1.5% of patients and no Grade ≥ 3 thrombocytopenia events observed. Early antitumor activity was observed across multiple tumor types, including ovarian, prostate, and breast cancer, with tumor shrinkage observed in heavily pre-treated participants, including those previously exposed to PARPi. Of the 4 efficacy evaluable patients with prostate cancer, 2 achieved a partial response (PR) per RECIST 1.1 criteria. Notably, clinical benefit was evident at even low dose levels, with a confirmed CR observed in a breast cancer patient at the 20 mg dose level, with the patient remaining on treatment for more than 10 months.

Dr. Sui Xiong Cai, Chief Executive Officer of our Company, commented: “We are delighted that the latest clinical data for senaparib and our two novel selective PARP1 inhibitors, IMP1734 and IMP1707, have been presented at the 2026 ESMO Congress. These data further demonstrate the steady progress of our synthetic lethality pipeline. The updated Progression-Free Survival (PFS) data from the Phase 3 FLAMES study of senaparib provide more mature evidence supporting senaparib as a first-line maintenance therapy for all advanced ovarian cancer patients, regardless of BRCA mutation status. The updated data from the IMP1734 monotherapy and combination cohorts with paclitaxel and abiraterone show that selective PARP1 inhibitors can be combined with both chemotherapy and endocrine therapy, with good efficacy and a manageable safety profile; and the first-in-human data for brain penetrant IMP1707 in patients with HRR-mutated advanced solid tumors shows good tolerability and preliminary efficacy, providing initial validation of this design. Looking ahead, we will continue to advance differentiated precision anti-cancer therapies, accelerate the global clinical development of our products, and deepen our collaboration with Eikon Therapeutics, in our effort to deliver tangible clinical benefits to cancer patients worldwide.”

ABOUT SENAPARIB (IMP4297)

Senaparib (派舒寧®) is a novel, highly potent PARP1/2 inhibitor independently developed by the Company. Its unique molecular structure ensures excellent target selectivity and a wide safety window. Senaparib capsules received NMPA approval in January 2025 as a first-line maintenance therapy for adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer achieving complete or partial response to platinum-based chemotherapy, and has been subsequently included in the NRDL in December 2025. The Company is actively advancing the clinical and regulatory development of senaparib globally. Its Marketing Authorisation Application (MAA) in Europe was formally accepted by the European Medicines Agency (EMA) in August 2025, with approval expected in the second half of 2026. Concurrently, the Company is pursuing life cycle management for senaparib, exploring combination therapy opportunities, and expanding into multiple indications.

ABOUT IMP1734

IMP1734 is a novel PARP1-selective inhibitor with high potency of inhibiting PARP1 and low activity of inhibiting PARP2. Preclinical in vivo models demonstrated high anti-tumor activities and a wide therapeutic window. The improved therapeutic index of IMP1734 over currently marketed non-selective PARP1/2 inhibitors supports its development as monotherapy and in combination with other agents. Overall, Phase I studies demonstrated relatively low rates of hematologic toxicity, and clinical activity was observed at most doses tested, as evidenced by target lesion size reduction and durable responses. In addition, tolerability and efficacy are being evaluated in combination with Abiraterone and Paclitaxel, respectively. Additional information about the clinical trials of IMP1734 can be found at <https://clinicaltrials.gov/study/NCT06253130>.

ABOUT IMP1707

IMP1707 is a novel PARP1-selective inhibitor with high potency in inhibiting PARP1 and low activity against PARP2, designed to penetrate the blood-brain barrier. Preclinical in vivo models demonstrated robust anti-tumor activities (complete tumor regression) and favorable brain penetration. IMP1707 is currently under investigation as monotherapy in an ongoing global Phase I/II clinical trial, with preliminary evidence of clinical activity observed in a molecularly selected patient population. Additional information about the clinical trials of IMP1707 can be found at <https://clinicaltrials.gov/study/NCT06907043>.

ABOUT IMPACT

Founded in 2009, we are a commercial-stage biotechnology company focused on advancing synthetic lethality (SL)-based precision anti-cancer therapies globally, delivering innovative treatments to address the unmet medical needs of cancer patients. IMPACT was successfully listed on the Main Board of The Stock Exchange of Hong Kong Limited on May 13, 2026 (Stock Code: 07630.HK). We have in-house discovered and developed one of the most comprehensive and advanced SL franchises and are one of only three companies with both commercial-stage PARP1/2 inhibitors and clinical-stage next-generation PARP1-selective inhibitors worldwide.

Our core product, senaparib (IMP4297), has already been commercialized, following its approval as 1L maintenance therapy for OC “all-comers” in China in January 2025, and is reimbursable for OC 1L “all-comers” since January 1, 2026. Senaparib also delivered the most favorable PFS outcome among PARP1/2 inhibitors (non head-to-head) for 1L maintenance therapy for OC “all-comers” in China, setting a new benchmark in this class.

Our major pipeline assets include the PARP1/2 inhibitor senaparib (IMP4297), PARP1-selective inhibitors (IMP1734 and IMP1707, co-developed with Eikon Therapeutics), ATR inhibitor (IMP9064), WEE1 inhibitor (IMP7068), and multiple other synthetic lethality target inhibitors.

Our continued growth is powered by an integrated R&D platform that enables innovation across both small molecules and emerging modalities, including ADCs and degraders. Additionally, we have forged partnerships with leading global biotech and China pharmaceutical companies to date, as validation of our pipeline and R&D platform.

Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: The Company cannot guarantee that it will be able to fully realize the potential of senaparib and successfully advance its development for additional indications or develop, or ultimately market, IMP1734 (EIK1003) and IMP1707 (EIK1004). Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
IMPACT Therapeutics, Inc
南京英派藥業股份有限公司
Dr. Sui Xiong CAI
Executive Director and Chief Executive Officer

Hong Kong, October 23, 2026

As at the date of this announcement, the Board comprises (i) Dr. Sui Xiong CAI, Dr. Ye Edward TIAN and Ms. Ning MA as executive Directors; (ii) Dr. Cong XU, Dr. Qiang XU and Mr. Tao LIU as non-executive Directors; and (iii) Dr. Edward Ming GUO, Mr. Chi Hung SIU and Dr. Liming SHAO as independent non-executive Directors.